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NZB/NZW F~ (B/W) 1 mice spontaneously develop an autoimmune disease characterized 
by  lupus  erythematosus  cell  formation,  immune  complex  glomerulonephritis,  and 
production of antibodies to DNA and RNA (1-4). They are considered a laboratory model 
for human  systemic lupus  erythematosus.  Genetic,  immunologic, and viral  factors are 
involved  in  the  pathogenesis  of their  disease  (5).  Recent  studies  implicate  a  loss  of 
suppressor  T  cells  (6,  7)  and  a  deficiency  of  thymic  hormone  (8,  9)  as  important 
contributing factors in their disorder. 
We reported the  development of monoclonal macroglobulinemia in one-third of B/W 
mice  over  the  age  of  12  mo  (10).  Monoclonal  IgM  was  associated  with  generalized 
lymphoproliferation  and  tumor  formation.  A  malignant  lymphoma  (141) secreting  a 
monoclonal IgM arose spontaneously in our colony and was established as a transplanta- 
ble tumor by serial passage into newborn and adult syngeneic recipients. An anti-idiotypic 
antiserum  to the  141 IgM was  prepared  and  used  to identify the secreted  monoclonal 
immunoglobulin in the serum of tumor transplant recipients (10). 
Idiotypic  determinants  on  the  surface  of  normal  B  lymphocytes  play  an 
important role as receptors for antigens. Anti-idiotypic serum can be sl:ecifically 
immunosuppressive,  suggesting  that  an  immune  response  directed  against 
idiotype  cell  receptors  may be  one  mechanism  for regulation  of the  antibody 
response  (11,  12).  Idiotypic determinants  on  the  surface  of malignant  plasma 
cells behave like tumor-associated transplantation antigens (13). Syngeneic mice 
immunized against the idiotypic determinants on myeloma proteins are specifi- 
cally protected against the corresponding plasma cell tumor which contains the 
idiotype on its cell surface (14). 
We have investigated the presence of idiotype on the surface of lymphoma 141 
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tumor  cells and  the ability of 141  IgM  to confer protective  immunity  against the 
tumor.  Our  results  show  that  protective  immunity  can  be  induced  by  prior 
immunization  against  the  monoclonal  IgM  and  demonstrate  cellular  mech- 
anisms  which  may  contribute  to this immunity. 
Materials  and Methods 
Mice.  B/W mice were from our colony maintained at the University of California, San Francisco, 
Calif.  2-  to  6-mo  old  mice  (three  to  five  mice  per  group)  were  used  in  the  tumor  protection 
experiments. 
Isolation  of IgM 141.  IgM  was isolated from serum by  10-35%  sucrose density gradient ultra- 
centrifugation in an  SW40  rotor (Beckman  Instruments, Inc.  Fullerton,  Calif.)  at  38,000  rpm for 
20 h. Ultracentrifugation was preceded by preparative agarose gel electrophoresis  in 0.05 Veronal (pH 
8.0)  or 20%  cold ethanol precipitation of three times diluted mouse serum. MOPC  104E  IgM is a 
Mtype  monoclonal  protein  produced  by  a  mineral  oil-induced transplantable  plasmacytoma of 
BALB/c mice (15).  This protein was purified from ascitic fluid in the same way as 141 IgM. 
Lymphoid Tumors  in B/WMice.  Two spontaneous transplantable lymphomas (141 and 10) are 
maintained in serial passage by subcutaneous or intraperitoneal inoculation of 0.2-0.5 ml of minced 
cells from nodular tumors or 0.5-1.0 ml of ascites containing tumor cells (10). Ceil transfers are made 
at about 2-wk intervals. Tumor 141 is histologically a lymphoblastic lymphoma producing IgM which 
originated from an enlarged spleen (16). This tumor is now in its 24th transplant generation. Tumor 
10 is a mixed lymphoma (lymphoblasts and reticulum cells) which originated from enlarged cervical 
and axillary lymph nodes. This tumor is now in its 10th transplant generation. 
Membrane  Localization  of Idiotype  by  Indirect  Immunofluorescence.  Fluorescein-conjugated 
goat antirabbit 7S IgG (Meloy Laboratories, Inc., Springfield, Va.) was used at a concentration of 1 
mg/ml. Rabbit anti-idiotypic serum to 141 IgM was prepared as previously described (10). 2 x  10Vml 
of lymphoma 141 cells were suspended in RPMI 1640 medium. (Grand Island Biological Co., Grand 
Island, N. Y.). 0.1 ml of cells was incubated with 0.1 ml of diluted rabbit anti-idiotype 141 at 0°C for 
30 min and washed in a large volume (12-15 ml) of medium. Washed cells were suspended in 0.1 ml of 
fluorescein-conjugated goat  antirabbit IgG  for 30  rain  at  0°C.  Cells were then washed in a  large 
volume of medium and resuspended in 50  ttl  of medium containing 50%  glycerol for microscopic 
study. After washing some cells were further incubated in culture medium at 37°C for various time 
periods in order to allow "capping" to take place. 
Fluorescence Microscopy.  A Zeiss microscope (Carl Zeiss, Inc., New York) was used with a BG12 
excitation filter and a 53/50 barrier filter. The light source was an Osram HBO-200 mercury arc lamp. 
Photographs were taken on High Speed Ektachrome 35-mm daylight film. 
Immunization of B/W Mice with 14I IgM and Transplantation  of Lymphoma 141 Cells.  Purified 
mouse IgM (141 or 104E),  human IgM, or bovine serum albumin in Freund's complete adjuvant were 
injected into B/W  mice in  multiple sites. The total  protein was  1.0  mg given in three weekly or 
biweekly injections. 1 wk after the last injection, mice were inoculated subcutaneously with different 
doses of 141  tumor cells (1  x  l0 s or  1.5  x  107). Every 3 days thereafter, mice were examined for 
palpable tumors and the diameter of the tumors was measured. Animals which showed delayed 
appearance of tumors were called protected mice, whereas animals regressing tumors were called 
regressor mice. 
5~Cr Labeling  o[ Lymphoma 141 Target Cells.  Ascitic tumor cells were harvested by aspiration 
and washed three times in RPMI  1640 medium. The  cell concentration was adjusted to 2  x  10 ~ 
cells/ml. 1 ml of this suspension was incubated with 200 ttCi of 5tCr (as sodium chromate, sp act > 100 
ttCi/ttg; International Chemical & Nuclear Corporation, Burbank,  Calif.) at 37°C for 30 min. The 
labeled cells were washed twice in 50 ml of RPMI 1640 medium and diluted to a final concentration of 
5  x  105 cells/ml. 
Preparation of Spleen Cells.  Spleens were removed from control and immunized mice and finely 
minced in RPMI 1640 medium. The resultant single cell suspension was washed three times and cells 
adjusted to 1 x  107 cells/ml of RPMI 1640 medium containing 10% heat-inactivated human serum. 
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Assay for Cell-Mediated Cytotoxicity.  The cell-mediated cytotoxicity test was performed by the 
method of Canty and Wunderiich with some modifications (17). 1 ml of control or immune spleen cell 
suspension (1 x  107 cells) and 0.1 ml of ~Cr-labeled tumor target cell suspension (5 x  10' cells), was 
pipetted into 35 x  10-mm plastic petri dishes (Falcon Plastics, Div. of BioQuest, Oxnard, Calif.). The 
immune cell to target cell ratio was 200:1. Cultures were performed with 2-3 replicates. Dishes were 
placed in horizontal trays on a rocking platform at 37°C in a  moist atmosphere of 90% air and 10% 
carbon dioxide.  Dishes were  rocked  continuously at 6  complete cycles/min during the incubation 
period of 7 or 15 h. After incubation, the contents of each petri dish were transferred into tubes with 1 
ml of cold medium and centrifuged at 400 g for 10 min. 1 ml of supernate from each tube was assayed 
for radioactivity (5~Cr release) in a  Packard ~-Scintillation counter (Packard Instrument Co., Inc., 
Downers Grove, Ill.). The specific cytotoxicity was then calculated as follows: 
Specific cytotoxicity (%)  - 
E-C 
T-C 
×  100. 
E,  cpm of ~Cr released from cells in the petri dish containing experimental ceils;  C,  cpm of 51Cr 
released from cells in the petri dish containing normal cells; and T, cpm of 5~Cr released from cells in 
the petri dish containing 1 ml of distilled water. 
Inhibition of cell-mediated cytotoxicity by 141 IgM or 104E IgM was performed by incubating 1.0 
ml of spleen cells (4 x  10Vml) with 1.0 ml of 141 IgM or 104E IgM (100 #g/ml or 160 ttg/ml) for 30 min 
at 37°C. After incubation, cells were washed and adjusted to 1 x  10Vml viable cells in RPMI 1640 
medium. 
Assay  for Complement-Dependent  Cytotoxicity.  Complement-dependent humoral cytotoxicity 
was determined by mixing 0.1 ml of 51Cr-labeled target cells with 0.1 ml of antl-idiotypic serum and 
0.1  ml  of  five  times  diluted  rabbit  serum  preabsorbed  with  lymphoma  141  cells.  The  percent 
cytotoxicity was calculated the same way as for cell-mediated cytotoxicity. 
Lymphocyte Transformation  by 141 IgM or I04E IgM.  Spleen cells from B/W mice preimmu- 
nized with IgM 141 and challenged with the corresponding 141 lymphoma were either pretreated with 
141 or 104E IgM before washing and culturing, or cultured in the presence of IgM (5-100 ttg/ml). The 
proteins were first dialyzed against RPMI 1640. Spleen cells from control B/W mice who were neither 
immunized  nor  challenged  with  tumor  were  handled  in  the  same  way.  Cultures  of  5.0  x  105 
lymphocytes in a final vol of 0.2 ml were established in microtiter plates, using RPMI 1640 medium 
containing  10  mM  Hepes  buffer  and  1%  antibiotic-antimycotic  mixture  (GIBCO).  They  were 
maintained in 5% CO~ at 37°C. 1 ttCi of tritiated thymidine (3,000 mCi/mM) was added 8-12 h before 
automated suction harvesting with saline, trichloracetic acid, and methonol on the 4th day (18). Data 
shown are  mean  ±  standard errors of counts per minute incorporated,  usually from three or four 
replicate  cultures.  The  difference  between  141  IgM-stimulated  incorporation  and  104E  IgM- 
stimulated incorporation in control spleen cells was compared with the corresponding difference in 
protected spleen cells using the Student's t  test.  Statistical significance was determined from the 
means and standard errors of the logarithms of the incorporated radioactivity, pooling the variance of 
the logarithms. 
Antibody Activity of 141 IgM.  Purified 141 IgM was studied for antibody activity against various 
antigens by the following methods: (a) Filter radioimmunoassay to detect antibodies to DNA or RNA 
{19),  (b)  bentonite flocculation test to  detect antimouse IgG  (20),  (c)  trypan  blue dye  exclusion 
method to detect antithymocyte antibody (21), (d) hemagglutination test to detect antired blood cell 
antibody, (e) immunodiffusion method to detect anti-al~3 dextran (courtesy of Dr. Roy Riblett, Salk 
Institute, San Diego,  Calif.), and (f) immunoprecipitation method to detect antimouse leukemia vi- 
rus antigens (courtesy of Dr. Richard Lerner,  Institute for Cancer Research, Philadelphia, Pa.). 
Results 
Idiotypic  Determinants  on  Cell  Surface  Membranes.  The  presence  of  idio- 
typic  determinants  on the surface of lymphoma  141 cells was demonstrated  by in- 
direct  immunofluorescence  using  rabbit  anti-idiotypic  antiserum  (Fig.  1).The  in- 1550 S.  SUGAI, D.  W. PALMER, N. TALAL, AND I. P.  WITZ  1551 
tensity of fluorescence diminished with dilution of the anti-idiotype serum, but 
some staining  was  still  seen  even  at  1:1,280 dilution  (Table  I).  To confirm the 
specificity of this staining reaction, inhibition studies were performed using puri- 
fied  monoclonal  IgM  from  lymphoma  141  and  from a  BALB/c plasmacytoma 
(MOPC  104E).  The  141  IgM  inhibited  the  fluorescent  staining  completely, 
whereas the  104E IgM had no effect (Table I). 
Two  further  specificity  controls  were  performed:  (a)  anti-idiotypic  serum 
prepared against another B/W monoclonal IgM (108) failed to show immunofluo- 
rescence against the  lymphoma 141  cells,  and  (b)  anti-idiotypic serum  against 
lymphoma 141  failed  to  show membrane  immunofluorescence against  another 
B/W transplantable lymphoma (10) maintained in our laboratory. Lymphoma 10 
does  have  surface  immunoglobulin  since  it  shows  membrane  immunofluores- 
cence with antiserum  against ~-heavy chain and K-light chain. 
TABLE I 
Detection of Idiotypic Determinants on Membranes of 
Lymphoma 141  Cells  by Treatment with Rabbit Antiserum to 
Idiotype 141 
Specific cytotoxicity$ 
Indirect im-  Titer of  Percent after inhibition  munofluo-  anti-141  by:  rescence*  Percent 
141 IgM  104E IgM 
80  +3§  92 
160  + 3  92  4 
320  + 3  92  5 
640  +2  91  0 
1,280  + 1  80 
2,560  0 
90 
93 
* After staining with fluorescein-conjugated,  goat antiserum to rabbit IgG, 
fluorescence was graded on a scale of 0 to +3. 
Specific release of ~lCr from 141 cells in the presence of complement, and 
after incubation of the anti-141 serum with 4 #g/ml of 141 or 104E IgM. 
§ Fluorescence was completely eliminated by inhibition with 141 IgM (25 
~g/ml) but not reduced by 104E IgM at the same concentration. 
We  attempted  to  induce  "capping"  by  exposure  of lymphoma  141  cells  to 
anti-idiotypic antiserum followed by incubation at 37 °C for various time periods. 
Only  about  10%  of  cells  showed  typical  "capping"  after  3-h  incubation;  the 
majority  of  cells  showed  membrane  localization  in  a  crescent  pattern  over 
approximately 30% of the cell surface  (Fig.  1). There was no increase in typical 
capping even when a  double antibody method was used (incubation with rabbit 
anti-idiotype and goat antirabbit  sera at 37°C for up to 12 h). 
Fro.  1.  Indirect immunofluorescence  of lymphoma 141 cells exposed to rabbit anti-idiotypic 
antiserum and fluorescent goat antirabbit  serum at 0°C for 30 min (a) or at 37°C for 3 h (b). 
Magnification: (a)  × 400, (b)  x 300. 1552  IDIOTYPE  OF IgM ON  NZB/NZW LYMPHOMA CELLS 
Additional  evidence for the presence of idiotypic determinants  on lymphoma 
141  cells  was  provided  by cytotoxicity studies  using  tumor  cells labeled with 
radioactive chromium.  The rabbit  anti-idiotypic  serum was highly cytotoxic in 
the  presence  of  complement.  As  with  the  immunofluorescent  studies,  this 
cytotoxicity was specifically inhibited by 141 IgM but not by 104E IgM (Table I). 
These  inhibition  studies  confirm  the  specificity  of  the  anti-idiotypic  serum 
against  cell  surface  immunoglobulins  and  indicate  the  accessibility  of  the 
idiotypic determinants  on the cell membrane. 
Protection Against Lymphoma 141 by Prior Immunization with 141 IgM.  Ex- 
periments  by  Lynch  and  colleagues  suggest  that  idiotypic  determinants  on 
induced BALB/c plasma cell tumors behave as tumor-associated transplantation 
antigens (13). We studied whether the idiotype of 141, a naturally occurring BfW 
lymphoma,  could function in the  same way. In the first experiment,  6-mo old 
B/W  male  mice  were  immunized  with  either  141  IgM  or  human  macro- 
globulinemic serum in complete Freund's adjuvant. After the third injection, the 
immunized mice received 1.5 ×  107 lymphoma 141 cells injected subcutaneously. 
Tumor nodules appeared in all mice 15 days later and grew progressively. Three 
out of five mice immunized with 141 IgM showed tumor regression starting about 
day 35 (Fig.  2). One regressor mouse was sacrificed for cytotoxicity studies (see 
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FIG.  2.  Tumor diameter  as  a  function of days after challenge with  lymphoma 141  cells in 
unimmunized (untreated)  and immunized (treated)  mice. The challenge inoculum was either 
1.5  x  107  cells  (A)  or  1.0  >  10 ~ cells  (B).  Three  mice  were  immunized with bovine serum 
albumin (BSA)  and three with a  human monoclonal IgM  (H-IgM). s. SUGAI, D. W. PALMER, N. TALAL, AND I. P. WITZ  1553 
below). The other two showed a gradual regrowth of tumor and died 2 and 3 mo 
later. Serum of these animals showed a positive immunoprecipitin reaction with 
anti-idiotypic antiserum on several occasions as well as a small amount of an M 
protein. Two mice immunized with human macroglobulinemic serum showed no 
regression of tumors. 
In a second experiment, 2-mo old mice were unimmunized or immunized with 
either  141  IgM,  104E  IgM,  human  monoclonal  IgM  from  a  patient  with 
Waldenstrom's macroglobulinemia, or bovine serum albumin. Tumor cells were 
again injected after the last immunization. A smaller number of lymphoma cells 
(1  ×  105) were inoculated, this representing the minimal lethal dose of tumor. 15 
of 16 control mice developed progressive tumors and died on the 35th day (Fig. 2). 
Four out of five mice immunized with 141 IgM had only a small tumor nodule on 
the 35th day. 
Because of the close similarity between 141 IgM and 104E IgM, it is of interest 
to compare the survival data of mice immunized with these monoclonal mouse 
macroglobulins. All seven mice immunized with 141  IgM survived past day 35 
after tumor grafting, whereas all five mice immunized with 104E IgM died before 
day 28.  These results are highly significant (p  <  0.001)  by chi square analysis 
with Yates modification. 
Mechanism of Protection against  Lymphoma 141.  Sera from mice regressing 
tumors were studied for cytotoxic activity against lymphoma 141  cells labeled 
with radioactive chromium. Whereas rabbit anti-idiotypic antiserum was highly 
cytotoxic (Table I), regressor sera killed only 7-20% of the tumor cells (compared 
to control sera from mice with progressive tumors which killed 1-5%  of tumor 
cells). These results suggest that humoral immunity against lymphoma 141 was 
present but rather weak. We could not detect any antibody-dependent cellular 
cytotoxicity using regressor sera and normal mouse spleen cells. 
By contrast, cellular cytotoxicity against lymphoma 141 was observed in four 
out of five protected mice studied (Table II). The degree of positive cytotoxicity 
varied from 26-88%.  The specificity of this cytotoxic activity was studied. In two 
TABLE II 
Cellular lmmunity Against Lymphoma 14I by Spleen Cells from 
Protected Mice 
Mouse no. 
Specific cytotoxicity* 
Percent 
Percent after inhibition by: 
141 IgM  104E IgM 
477  88 
505  9 
501  27  5  23 
536  26  0  23 
537  45 
*  Specific release  of 5~Cr from 141 cells  in the absence of complement, and 
after  treatment of cytotoxic spleen cells  with 141 or 104E IgM. 1554  IDIOTYPE OF IgM ON  NZB/NZW LYMPHOMA CELLS 
experiments  (mice 536  and  537),  spleen  cells were  cytotoxic against lymphoma 
141 but not against lymphoma  10. Moreover, in mice 501 and 536, cytotoxicity by 
spleen  cells could be specifically blocked by prior incubation  with  141  IgM but 
not with  104E  IgM  (Table II). These results suggest the presence in protected or 
regressor  mice of spleen  cells specifically cytotoxic for lymphoma  141,  presum- 
ably by virtue of idiotypic recognition. 
The  presence of such spleen cells capable of recognizing idiotype was detected 
by a  second assay procedure.  Spleen cells from protected  mice were exposed to 
141  or  104E  IgM  in  tissue  culture  and  the  incorporation of  [3H]thymidine  into 
DNA  was  measured.  Responses  were  compared  with  control  B/W  mice.  In 
general,  neither  protein  stimulated  DNA  synthesis  in  control  spleen  cells, 
whereas  141  IgM  but  not  104E  IgM  stimulated  DNA  synthesis  in  cells  from 
experimental  mice (Table III). In  the  first  experiment,  the  specific proliferative 
response to 141 IgM was partially dependent  upon the concentration of IgM used 
to stimulate  the cells. In the second experiment, a specific response was obtained 
by leaving the IgM in the cultures but not by removing it before culturing. In the 
third  experiment,  metastases  to  the  spleen  reduced  baseline synthesis  10-fold, 
but  responsiveness  specific  for  141  IgM  was  still  evident.  Thus,  in  all  three 
experiments,  there  was  stimulation  of spleen  cells from  protected  mice  by  141 
IBM but  not by 104E  IgM. 
Lack  of Detectable Antibody Activity in 141  IgM.  About  5%  of monoclonal 
TABLE III 
Specificity of the In Vitro DNA Synthetic Response to IgM 14I  by Spleen Cells from 
Protected Mice 
Protocol*  Incorporation of pH]TdR (cpm ±  SE) after: 
Concen-  Mouse 
Exp.  tration  Wash  No IgM  1411gM 
of IgM 
104EIgM 
yg/ml 
I  5  +  Control  3,877  ± 518  3,804 ± 254  3,509 ~ 800 
5  +  501  6,189 ± 38  10,899 ± 336  8,499 ~ 875 
p  <0.2 
50  +  Control  3,877  ± 518  2,221 ± 190  3,501  ~ 123 
50  +  501  6,189 ± 38  10,187 ~ 645  7,206 ± 222 
p  < 0.001 
50  ÷  Control  1,958  ± 22  3,180 ± 127  2,505 ± 98 
50  +  536  3,806 ± 121  2,605 ± 84  2,659 ± 284 
83  -  536  4,902  --  12,264  --  3,917  -- 
III  100  -  Control  5,401  ± 1,084  5,414 ± 844  6,736 ± 707 
100  -  535  537  ± 45  1,306 ± 173  459  ± 6 
p  < 0.001 
* Spleen cells incubated with various concentrations of 141 or 104E IgM were either cultured directly 
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immunoglobulins have been shown to combine with specific antigens (15,  22). 
MOPC  104E,  for example, reacts with al -* 3 dextrans (15).  Many monoclonal 
IgMs  in  humans  are  antigamma  globulins  and  have  rheumatoid  factor-like 
properties  (22,  23).  We have tried to find an antibody activit:¢ for the 141 IgM 
that arose spontaneously in B/W mice. We are unable to detect activity against 
DNA or RNA, mouse gamma globulin, mouse erythrocytes, mouse thymocytes, 
al -~ 3 dextran, or mouse leukemia viral antigens. 
Discussion 
This  study demonstrates the  presence  and  potential  significance of idiotypic 
determinants on the surface membranes of an IgM-producing lymphoma (141) 
that arose spontaneously in B/W mice. The presence of idiotype was shown by 
immunofluorescence and  cytotoxicity using a  rabbit  anti-idiotypic antiserum. 
The specificity was confirmed by inhibition with 141 IgM but not with 104E IgM, 
a  monoclonal IgM produced by an oil-induced plasmacytoma of BALB/c origin. 
Moreover, another B/W lymphoma (10) failed to show membrane fluorescence 
with anti-idiotypic serum directed against 141. 
Surface  membrane immunoglobulins  are a distinguishing  characteristic  of normal  and 
malignant B lymphocytes. In normal human peripheral  blood, about 25% of circulating 
lymphocytes show surface  immunoglobulin  by  immunofluorescenee  with  polyvalent 
antiserum (24). In chronic lymphocytic leukemia, almost 100% of circulating lymphocytes 
show membrane immunoglobulin  and are classified as B lymphocytes.  This membrane 
immunoglobulin is often monoclonal, belonging to either the IgG or IgM immunoglobulin 
class (25), 
In Waldenstrom's macroglobulinemia, the majority of circulating lymphocytes contain 
the  monoclonal  IgM  on  their  cell  surface  (25). Indeed,  in  Waldenstrom's  macro- 
globulinemia  and  cold  agglutinin  disease,  the  secreted  monoclonal  IgM  and the  cell 
surface IgM have the same idiotype as shown by cytotoxicity (26). This result indicates 
that the same unique antigenic determinants are present  both on the secreted immuno- 
globulin and on the cell surface immunoglobulin. 
The  potential  significance  of  finding  idiotypic  determinants  on  the  surface 
membranes is shown by their ability to function as tumor-associated transplan- 
tation antigens. Our experiments relate to the work of Eisen and associates who 
first  observed  that  BALB/c  mice  produced  "autoimmune-like"  antibodies 
against unique idiotypic determinants present in the ligand-combining sites of 
some functional BALB/c myeloma proteins  (27).  They next observed (13) that 
such  immunized mice could specifically suppress  growth of the corresponding 
transplanted tumor cells (either MOPC-315  or MOPC-460).  In all, they found 
anti-idiotypic antibody responses in BALB/c mice to 6 of 7 myeloma proteins, 
and in three cases, animals making an anti-idiotypic response suppress growth of 
the corresponding plasmacytoma (H. N. Eisen, personal communication). They 
did not look for cell-mediated immunity in their protected mice, but considered 
cellular immunity directed against idiotypic determinants as a  possibility. 
Our experiments with a  natural tumor of B/W mice extend Eisen's observa- 
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idiotype  is  present  in  the  spleens  of regressor  and  protected  mice.  Both  by 
cytotoxicity and  lymphocyte stimulation,  evidence  was  obtained  for  cellular 
sensitization to the syngeneic 141 IgM. Four out of five cytotoxicity  experiments 
were positive, and in each of two experiments, cellular cytotoxicity  was inhibited 
by 141 IgM but not by 104E IgM. Likewise, splenic lymphocytes from protected 
mice were stimulated to synthesize DNA by 141 IgM but not by 104E IgM. Thus, 
this phenomenon appears to represent cellular "autoimmunity"  directed against 
idiotype, the counterpart of Eisen's finding with humoral immunity. 
Recognition of antigenic determinants on  141  IgM that are not idiotypic are 
largely excluded by using the 104E IgM as a  control. The lack of another BAV 
monoclonal IgM prevents further specificity controls at this time. However, since 
idiotypic determinants are known to function as tumor-associated transplanta- 
tion antigens conferring protective immunity (13),  and since idiotypic determi- 
nants  are  accessible  on  the  surface  membranes  of  lymphoma  141  cells,  we 
interpret our results to suggest cellular recognition of idiotype as the most likely 
protective mechanism. 
Our failure to detect much humoral immunity against idiotype in the protected mice may 
be due to lack of an assay such as Eisen employed that measures the interaction between 
monoclonal antibody, anti-idiotype, and specific ligand (27). Such an assay depends upon 
a known functional activity for the monoclonal protein,  which we have been unable to 
find. 
The nature of the cytotoxic cell will be studied in future experiments. We presume it to 
be a T lymphocyte. Rollinghoff and Wagner have recently shown  that T cells are required 
for both the induction of immunity and the effector phase of cell-mediated  cytotoxicity 
directed  against plasmacytomas (28). Furthermore, allotype  suppression  requiring  the 
active presence of T lymphocytes has been reported  (29). 
The presence of lymphocytes with receptors capable of recognizing idiotype may 
also have important implications for immune regulation. Anti-idiotypic serum 
can  be  specifically  immunosuppressive.  For  example,  anti-idiotypic  serum 
directed against receptors for phosphorylcholine can suppress a normal immune 
response to phosphorylcholine (11). A theory of regulation based on antireceptor 
(idiotype) recognition has been proposed as a means for limiting the extent of an 
immune response (12, 30).  Our findings suggest that cellular as well as humoral 
mechanisms may participate in such regulation. Indeed, lymphocytes capable of 
recognizing idiotype receptors on other lymphocytes could function as suppressor 
cells  by releasing  cytotoxic or  inhibitory factors.  If the  receptors  were  those 
capable of binding autoantigens, such a  suppressor mechanism could function 
normally to prevent the proliferation of autoantibody producing clones and the 
release  of  autoantibodies.  The  lack  of  such  a  regulatory  mechanism  might 
contribute  to  some  types  of autoimmune  and  lymphoproliferative disorders. 
Moreover,  the  generation  of  lymphocytes  capable  of  recognizing  idiotype 
receptors  for autoantigens might have therapeutic potential in these diseases. 
Since functional monoclonal proteins exist in mice (15),  this possibility can be 
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Summary 
A  spontaneous  lymphoma  (141)  producing  monoclonal  IgM  is  established  in 
NZB/NZW F1  (B/W)  mice who spontaneously develop an autoimmune disease. 
Idiotypic determinants  of 141 IgM are present on the lymphoma cell surface as 
shown  by  indirect  immunofluorescence  and  specific  cytotoxicity with  rabbit 
anti-idiotypic antiserum. Fluorescence and cytotoxicity are inhibited by 141 IgM 
but not by 104E IgM, a monoclonal IgM produced by a BALB/c plasmacytoma. 
Immunization of B/W mice with 141 IgM before transplantation of lymphoma 
141  confers protective immunity. No such protection occurs after immunization 
with  104E IgM or other unrelated proteins. Protected mice contain spleen cells 
cytotoxic for 141  lymphoma cells.  This cytotoxicity is blocked by incubation of 
spleen cells with 141 IgM but not with 104E IgM. Moreover, splenic lymphocytes 
from protected mice are stimulated  to synthesize DNA by 141  IgM  but not by 
104E  IgM.  These  results  suggest  that  specific  cellular  immune  responses  to 
idiotypic  determinants  may  participate  in  the  observed  protection  against 
challenge with the corresponding B-cell tumor. 
Received for publication 18 July 1974. 
References 
1.  Burnet, F.  M.,  and M.  C.  Holmes.  1965. The natural  history of the NZB/NZW F1 
hybrid mouse: a laboratory model of systemic lupus. Australas Ann. Med. 14:185. 
2.  Aarons,  L.  1964. Renal  immunofluorescence in  NZB/NZW MICE.  Nature (Lond.). 
203:1080. 
3.  Lambert,  P.  H.,  and F.  J.  Dixon.  1968. Pathogenesis of the  glomerulonephritis of 
NZB/W mice. J. Exp. Med.  127:507. 
4.  Talal,  N.,  and  A.  D.  Steinberg.  1974. The pathogenesis of autoimmunity in New 
Zealand Black Mice. Curr.  Top. Microbiol. Immunol. 64:79. 
5.  Talal, N. 1970. Immunologic and viral factors in the pathogenesis of systemic lupus 
erythematosus. Arthritis.  Rheum. 13:887. 
6.  Barthold, D. R., S. Kysela, and A. D. Steinberg. 1974. Decline in suppressor T  cell 
function with age in female NZB mice. J. Immunol.  112:9. 
7.  Allison,  A. C.,  A. M. Denman, and R. D. Barnes. 1971. Cooperating and controlling 
functions of thymus-derived lymphocytes in relation to autoimmunity. Lancet. 1:135. 
8.  Bach, J. F., M. Dardenne, and J. C. Salomon. 1973. Studies of thymus products. IV. 
Absence of serum thymic activity in adult NZB and (NZB  x  NZW) F~ mice. Clin. 
Exp. Immunol.  14:247. 
9.  Talal, N., M. Dauphinee, R. Pillarisetty, and R. Goldblum. 1974. Effect of thymosin 
on thymocyte proliferation and autoimmunity in NZB mice. Ann. N.  Y. Acad. Sci. 
In press. 
10.  Sugai,  S.,  R.  Pillarisetty,  and  N.  Talal.  1973. Monoclonal  macroglobulinemia  in 
NZB/NZW F~ mice. J. Exp. Med.  138:989. 
11.  Cosenza, H., and H. Kohler. 1972. Specific suppression of the antibody response by 
antibodies to receptors. Proc.  Natl. Acad. Sci. U. S. A. 69:2701. 
12.  Rowley, D. A., F. W. Fitch, E. P. Stuart, H. Kohler, and H. Cosenza. 1973. Specific 
suppression  of  immune  responses.  Antibody  directed  against  either  antigen  or 1558  IDIOTYPE OF IgM ON NZB/NZW LYMPHOMA CELLS 
receptors  for  antigen  can  suppress  immunity  specifically.  Science  (Wash.  D.  C.) 
181:1133. 
13.  Lynch,  R.  G.,  R.  J.  Graff,  S.  Sirishinha,  E.  S.  Simms,  and  H.  N.  Eisen.  1972. 
Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. 
U. S. A. 59:1540. 
14.  Hannenstad, K., M. S. Kao, and H. M. Eisen. 1972. Cell-bound myeloma proteins on 
the surface of myeloma cells.  Potential targets for the immune system. Proc. Natl. 
Acad. Sci.  U. S. A. 69:2295. 
15.  Potter, M.  1972. Immunoglobulin-producing tumors and myeloma proteins of mice. 
Physiol. Rev. 52:631. 
16.  Greenspan,  J.  S.,  G.  A.  Gutman,  N.  Talal,  I.  L.  Weissman,  and  S.  Sugai.  1974. 
Thymus-antigen and  immunoglobulin positive  cells  in  lymph nodes,  thymus and 
malignant lymphomas of NZB/NZW mice. Clin. Immunol. lmmunopathol. 3:32. 
17.  Canty, T.  G.,  and J. R.  Wunderlich.  1970. Quantitative in vitro assay of cytotoxic 
cellular immunity. J. Natl.  Cancer Inst. 45:761. 
18.  Hartzman,  R.  J.,  M.  L.  Bach, F.  H. Bach,  G.  B. Thurman,  and K. W.  Sell.  1972. 
Precipitation  of radioactively labeled  samples:  a  semi-automatic  multiple-sample 
harvester.  Cell.  Immunol. 4:182. 
19.  Attias, M. R., R. A. Sylvester, and N. Talal.  1973. Filter radioassay for antibodies to 
reovirus RNA in systemic lupus erythematosus. Arthiritis. Rheum. 16:714. 
20.  Bozicevich, J., J. J. Bunim, J. Freund, and S. B. Ward. 1958. Technique of bentonite 
flocculation test for rheumatiod arthritis.  Proc.  Soc. Exp. Biol. Med. 97:180. 
21.  Shirai,  T.,  and  R.  C.  Mellors.  1971. Natural  thymocytotoxic autoantibody  and 
reactive antigen in New Zealand black and other mice. Proc. Natl. Acad. Sci. U. S. A. 
68:1412. 
22.  Seligman, M., and J. C. Brouet. 1973. Antibody activity of human myeloma globulins. 
Semin. Hematol. 10:163. 
23.  Kunkel,  H.  G.,  V.  Agnello,  F.  G. Joslin,  R. J.  Winchester,  and J. D. Capra.  1973. 
Cross-idiotypic  specificity  among  monoclonal  IgM  proteins  with  anti-~/-globulin 
activity. J. Exp. Med. 137:331. 
24.  Williams,  R.  C.,  Jr.,  J.  R.  DeBoard,  O.  J.  Mellbye,  R.  P.  Messner,  and  F.  D. 
Lindstrom. 1973. Studies of T  and B lymphocytes in patients with connective tissue 
diseases. J.  Clin. Invest. 52:283. 
25.  Preud'homme, J.  L., and M.  Seligman. 1972. Surface bound immunoglobulins as a 
cell marker in human lymphoproliferative diseases. Blood J. Hematol. 49:777. 
26.  Wernet, P., T. Feiz, and H. G. Kunkel. 1972. Idiotypic determinants of immunoglobu- 
lin M  detected on the surface of human lymphocytes by cytotoxicity assays. J. Exp. 
Med. 136:650. 
27.  Sirisinha, S., and H. N. Eisen. 1971. Autoimmune-like antibodies to the ligand-bind- 
ing ~ites of myeloma proteins. Proc. Natl. Acad. Sci. U. S. A. 68:3130. 
28.  Rollinghoff, M., and H. Wagner. 1973. In vitro induction of tumor specific immunity: 
requirements  for  T  lymphocytes  and  tumor  growth  inhibition  in  vivo.  Eur.  J. 
Immunol. 3:471. 
29.  Herzenberg, L. A.,  E. L. Chan, M. M. Ravitch, R. J. Riblet,  and L. A. Herzenberg. 
1973.  Active  suppression  of  immunoglobulin  allotype  synthesis.  J.  Exp.  Med. 
137:1311. 
30.  Jerne,  N.  K.  1974. Clonal selection in a  lymphocyte network. In  Cellular Selection 
and  Regulation  in  the  Immune  Response.  G.  M.  Edelman,  editor.  Raven  Press, 
New York,  39. 